Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets.
Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA. The significant limitations of existing solutions prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Codex DNA’s solution is the BioXp™ system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease of use and hands-free automation. Codex DNA believes the BioXp™ system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development, and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics, and precision medicines.
Member count: 51-200
Phone: +1 855-474-4362
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | BroadOak C... | broadoak.c... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 09.02.2022 | Codex DNA ... | SAN DIEGO, Feb. 09, 2022 (GLOB... | - | - | marketscre... |
| 23.12.2021 | Codex DNA ... | SAN DIEGO, Dec. 23, 2021 (GLOB... | - | - | marketscre... |
| 11.11.2021 | Codex DNA ... | SAN DIEGO, Nov. 11, 2021 (GLOB... | - | - | marketscre... |
| 10.08.2021 | Codex DNA ... | SAN DIEGO, Aug. 10, 2021 (GLOB... | - | - | marketscre... |